Pharmaceutical Brand Spending Focus Shifts to Commercialization During Registration and Launch

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Senior Research Analyst

Pharmaceutical brand spending varies dramatically from early-stage brand development to pharma brand launch.  During pre-clinical to Phase 2 clinical trials, brand teams skew support toward medical affairs activities.  However, by late-stage development—and especially as pharma brands prepare to enter the market—brand teams must shift their focus to commercialization efforts. Continue reading


Pharma Companies Focus Pre-Clinical New Product Planning on Medical Affairs Expenditures

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Senior Research Analyst

Pharmaceutical brand spending is a key consideration as commercialization groups begin new product planning.  Life sciences companies must be able to right-size brand support across many functions. Throughout a product’s lifecycle, brand teams must be able to determine budget allocation across medical affairs, market access and marketing expenditures.  In the early stages of new product planning, commercialization groups often focus pharma brand spending on medical affairs activities. Continue reading




Pharmaceutical Brand Marketing: Begin Brand Assessment As Soon As Pre-Clinical Development

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Life sciences companies rely on brand assessments and market research to form the foundation of pharmaceutical commercialization strategies.  Often, companies begin these activities early in the product lifecycle to prepare for future pharmaceutical brand marketing activities.  In some cases, brand teams begin product assessments and commercial landscape assessments as early as pre-clinical development.  Early assessments allow teams to coordinate support activities across internal stakeholders.  These assessments also guide firms in determining best-fit pharmaceutical launch and marketing budgets.     Continue reading


Medical Device Commercialization: Rightsizing Investments to Match Approval Pathway Complexity

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Developing and commercializing medical devices can quickly become a costly endeavor.  Overall, medical device commercialization investments increase alongside development duration.  Commercial boards are charged with optimizing investments in device development and product launch. While these boards work to minimize costs, key factors—including device complexity and development time impact total investments.  More complex products, typically those requiring pre-market approval (PMA), often require more funding than those seeking 510(k) clearance. Continue reading


Medical Device Brands: New Products Face Heavy Competition in the US Market

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

It’s no secret that the life sciences commercial landscape is saturated with established brands, and that more products enter the market each year.  Companies must have a strong understanding of their major competitors early in product development as they prepare for launch.  However, medical device brands are very different even from their closest competitors.  As such, companies can expect their products to enter markets with varying degrees of commercial competition.  While some therapeutic areas are more competitive than others, product novelty is also a determining factor as new product planning and commercial executives prepare for launch. Continue reading


Something to Talk About: Gathering the Patient Voice to Inform Customer-Centric Marketing Strategies

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Today, patients are more involved in their own healthcare decisions than ever before.  While pharmaceutical firms shift their commercial targets to include payer and government systems, marketing and sales teams also benefit by reaching out to their end-users.  Thanks to the abundance of information available on the Internet, as well as a number of health-focused mobile applications, patients are able to more actively engage with doctors and influence treatment plans.  To accommodate these more active consumers, companies should look to patient-centric marketing strategies as an integral part of their commercial mix. Continue reading


Medical Device Development: Looking to External Resources to Drive Product Management

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Life sciences firms consume a lot of resources — both budgets and time — on medical device development and commercializing their brands.  While many companies prefer to keep development in-house, others look to outside resources to supplement internal capabilities or to bolster their portfolios. For many companies, collaboration or acquisitions are viable options to move medical devices to market. Continue reading


Don’t Call it a Comeback: mHealth Never Went Out of Style

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Across the life sciences industry, global not-for-profit partnerships and pharmaceutical manufacturers alike have become increasingly active in the mobile health space.  In 2012, projections indicated that the global smartphone application market would reach up to $718 million. Already, mobile technologies had helped pharmaceutical and device teams facilitate heightened medical awareness and encourage patient adherence.  Continue reading